No Data
No Data
No Data
No Data
No Data
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed
GlobeNewswireApr 24 16:00 ET
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance with additional
GlobeNewswireApr 9 16:00 ET
Express News | Mural Oncology Shares Are Trading Higher After Morgan Stanley Initiated Coverage on the Stock With an Overweight Rating and a $13 Price Target
Moomoo 24/7Apr 4 07:57 ET
Mural Oncology Initiated at Overweight by Morgan Stanley
Mural Oncology Initiated at Overweight by Morgan Stanley
Dow JonesApr 4 06:49 ET
Express News | Morgan Stanley Initiates Coverage On Mural Oncology With Overweight Rating, Announces Price Target of $13
Moomoo 24/7Apr 4 06:39 ET
Mural Oncology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 186.98% Morgan Stanley → $13 Initiates Coverage On → Overweight
BenzingaApr 4 06:37 ET
jimmy james mendoza : what was there a circuit breaker on?
KhemistOP jimmy james mendoza: this.. MURA
KhemistOP :
No Data
No Data